) Astrocytic brain tumors are among the most lethal and morbid tumors of adults, often occurring during the prime of life. The current system of diagnosis and classification of brain tumors is partially predictive of outcomes, and remains based primarily upon morphologic criteria. Although recent work has shown a number of genetic differences which are critical in the oncogenesis and progression of astrocytic tumors, there is insufficient data to develop a molecular classification system. The availability of cDNA clones, large amounts of sequence, data and the technology for cDNA arrays provides a platform for the large scale analysis of gene expression in astrocytoma. We propose to identify a set of genes that will allow the molecular characterization of brain tumors by using cDNA microarray technology. Using a flexible microarray format will enable us to easily alter the arrayed genes whose expression patterns are most informative allowing us to create cost-effective glial tumor-related reagents. It is our central hypothesis that a much more detailed analysis of the genes that are expressed in astrocytomas will provide a more precise prognostic ability, subgroup patients for optimal treatment, and help identify appropriate therapeutic targets, subgroups patients for optimal treatment 1)To determine the optimal means of sampling low grade astrocytomas, anaplastic astrocytomas, and glioblastoma multiformes, to determine the degree of molecular heterogeneity within astrocytic tumors, to determine whether the heterogeneity is greater between tumors than within an individual tumor at each gene, and to determine the level of variance of each gene on the microarray. 2)To determine the gene expression profiles of 120 excisional glioma and meningioma brain tumor biopsies to develop a reclassification of the tumors based on gene expression profiles. 3)To develop a set of genes with prognostic importance in low grade astrocytomas. 4)To validate the importance of the genes from specific aims 2 and 3 in the prognosis of low grade astrocytomas.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01CA088127-01
Application #
6196583
Study Section
Special Emphasis Panel (ZCA1-SRRB-7 (M1))
Program Officer
Jacobson, James W
Project Start
2000-08-01
Project End
2005-01-31
Budget Start
2000-08-01
Budget End
2001-01-31
Support Year
1
Fiscal Year
2000
Total Cost
$340,146
Indirect Cost
Name
University of California Los Angeles
Department
Pediatrics
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Wang, Yinglin; Zhu, Shaojun; Cloughesy, Timothy F et al. (2004) p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition. Oncogene 23:1283-90
Lu, Kan V; Jong, Kimberly A; Rajasekaran, Ayyappan K et al. (2004) Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line. Lab Invest 84:8-20
Mischel, Paul S; Shai, Ruty; Shi, Tao et al. (2003) Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene 22:2361-73
Mischel, Paul S; Nelson, Stanley F; Cloughesy, Timothy F (2003) Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy. Cancer Biol Ther 2:242-7
Choe, Gheeyoung; Horvath, Steve; Cloughesy, Timothy F et al. (2003) Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 63:2742-6
Mischel, Paul S; Cloughesy, Timothy F (2003) Targeted molecular therapy of GBM. Brain Pathol 13:52-61
Shai, Ruty; Shi, Tao; Kremen, Thomas J et al. (2003) Gene expression profiling identifies molecular subtypes of gliomas. Oncogene 22:4918-23
Saghizadeh, Mehrnoosh; Brown, Donald J; Tajbakhsh, Jian et al. (2003) Evaluation of techniques using amplified nucleic acid probes for gene expression profiling. Biomol Eng 20:97-106
Mischel, Paul S; Umbach, Joy A; Eskandari, Sepehr et al. (2002) Nerve growth factor signals via preexisting TrkA receptor oligomers. Biophys J 83:968-76
Choe, Gheeyoung; Park, Jun K; Jouben-Steele, Lisa et al. (2002) Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. Clin Cancer Res 8:2894-901